Detalhe da pesquisa
1.
Focused ultrasound-mediated blood-brain barrier opening is safe and feasible with moderately hypofractionated radiotherapy for brainstem diffuse midline glioma.
J Transl Med
; 22(1): 320, 2024 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38555449
2.
Medulloblastoma: an Old Diagnosis with New Promises.
Curr Oncol Rep
; 22(9): 90, 2020 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32643099
3.
Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists.
Proc Natl Acad Sci U S A
; 111(2): 781-6, 2014 Jan 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24379381
4.
Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.
Proc Natl Acad Sci U S A
; 110(7): 2617-22, 2013 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-23359692
5.
Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.
Proc Natl Acad Sci U S A
; 109(5): 1655-60, 2012 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-22307626
6.
Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
BMC Cancer
; 14: 847, 2014 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-25410881
7.
Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.
Proc Natl Acad Sci U S A
; 108(9): 3755-60, 2011 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21321192
8.
Elucidation and Pharmacologic Targeting of Master Regulator Dependencies in Coexisting Diffuse Midline Glioma Subpopulations.
bioRxiv
; 2024 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38559080
9.
Immune Response following FLASH and Conventional Radiation in Diffuse Midline Glioma.
Int J Radiat Oncol Biol Phys
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38364947
10.
Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
Prostate
; 73(8): 873-83, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23280565
11.
Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].
Anticancer Drugs
; 24(2): 150-7, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23080077
12.
Hormonal manipulation of benign prostatic hyperplasia.
Curr Opin Urol
; 23(1): 17-24, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23202285
13.
Leptomeningeal dissemination in pediatric brain tumors.
Neoplasia
; 39: 100898, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37011459
14.
Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
Cancer
; 118(3): 670-80, 2012 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21751186
15.
Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
J Urol
; 187(4): 1498-504, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22341819
16.
Inhibitory effects of GHRH antagonists on human GH-secreting adenoma tissue.
Neuroendocrinology
; 96(1): 81-8, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22377963
17.
Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
Anticancer Drugs
; 23(9): 906-13, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22926257
18.
Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients.
Neuro Oncol
; 24(10): 1763-1772, 2022 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35148412
19.
LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.
Prostate
; 71(7): 736-47, 2011 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20945403
20.
Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.
Anticancer Drugs
; 20(7): 553-8, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19491659